For Mathieu, the ideal type 1 candidate for an SGLT-2 is someone living with overweight or obesity and is not using an insulin pump (research has shown that DKA most commonly occurs in women who use insulin pumps)
Managing side effects Anticipating side effects and implementing management strategies from the outset improves treatment outcomes
Demand for GLP-1 medications has surged in recent years, but cost and injectable delivery have limited access for many patients
These advances highlight a transition towards individualized, technology-enhanced diabetes management, ensuring better results for patients globally [5]
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity." Published in JAMA Network Open, Accessed on November 13, 2023 at Nature Medicine Journal
[17] Supporting Muscle Preservation During periods of caloric restriction, maintaining muscle mass becomes challenging